

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/48, 31/19	A1	(11) International Publication Number: WO 95/13048 (43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/12745 (22) International Filing Date: 4 November 1994 (04.11.94) (30) Priority Data: 08/150,942 12 November 1993 (12.11.93) US 08/209,041 9 March 1994 (09.03.94) US (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventor: BISSETT, Donald, Lynn; 3925 Dust Commander Drive, Hamilton, OH 45011 (US). (74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).		(81) Designated States: CA, CN, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: DESQUAMATION COMPOSITIONS CONTAINING SALICYLIC ACID AND ZWITTERIONIC COMPOUNDS (57) Abstract The subject invention relates to desquamation compositions comprising a combination of salicylic acid and certain zwitterionic surfactants. The subject invention further relates to methods of desquamation in mammalian skin and treating acne in mammalian skin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESQUAMATION COMPOSITIONS CONTAINING
SALICYLIC ACID AND ZWITTERIONIC COMPOUNDS

Technical Field

The subject invention relates to the field of skin conditioning. Specifically,
5 the subject invention relates to methods for improving the suppleness or smoothness
of skin by removing scales from skin surface.

Background

Skin is composed of two layers: the epidermis (or cuticle) and the dermis.
The epidermis is a thin outer layer composed of stratified epithelium. The outermost
10 layer of the epidermis is the stratum corneum which is composed of keratin protein-
filled, flattened cells surrounded by thin lipid layers. The cells are believed to be
attached to one another by protein connections (desmosomes) between cells. The
cells in the deepest portion of the epidermis, the basal layer, multiply and grow,
pushing the older cells of the epidermis upward and toward the surface. As these
15 cells move upward they become flattened. The epidermis is generally devoid of
blood vessels and depends on blood vessels found in the dermis for nutrition. The
more superficial cells of the epidermis, being far removed from the nutrient supply,
gradually differentiate, transforming their proteins into keratin. This process of
keratinization results in the death of the cells. Keratin is an insoluble proteinaceous
20 material and gives the stratum corneum a horn-like consistency. The outermost dead
stratum corneum cells are gradually shed and replaced by more recently keratinized
cells.

In normal skin, the stratum corneum is shed as individual cells or as small
clusters of cells. Skin problems such as dry skin, psoriasis, ichthyosis, dandruff, acne,
25 callus, photodamaged skin, aged skin, and sunburn can be described as disorders of
keratinization in which the shedding of stratum corneum cells at the skin surface is
altered relative to normal, young, healthy skin. Such alteration results in large
clusters of cells leading to visible scaling of the skin, a build-up of keratinaceous
material on the surface or in follicles or ducts and/or a rough texture to the skin
30 surface. These conditions may be improved by removal of the outermost
keratinaceous material.

For the foregoing reasons, there is a need for an efficacious agent for
removing surface scales from the stratum corneum of mammalian skin.


It is an object of the subject invention to provide topical compositions for
35 desquamation (scale removal) from the stratum corneum of mammalian skin.

It is a further object of the subject invention to provide such compositions
which are gentler and less irritating to the skin than existing compositions.

It is also an object of the subject invention to provide methods for removal of scales in mammalian skin.

Summary

The subject invention involves a combination of salicylic acid and certain
 5 zwitterionic surfactants having the structure:



wherein

- (a) R^1 is unsubstituted, saturated or unsaturated, straight or branched chain alkyl having from about 9 to about 22 carbon atoms;
- 10 (b) m is an integer from 1 to 3;
- (c) n is 0 or 1;
- (d) R^2 and R^3 are, independently, alkyl having from 1 to about 3 carbon atoms, unsubstituted or mono-substituted with hydroxy;
- (e) R^4 is saturated or unsaturated, straight or branched chain alkyl, which is
 15 unsubstituted or mono-substituted with hydroxy, having from 1 to about 5 carbon atoms; and
- (f) X is CO_2 , SO_3 or SO_4 .

Such a combination and compositions comprising it satisfy the need for an efficacious, easily administered agent for desquamation of skin, having little or no
 20 undesirable side effects. The subject invention is also directed to a method of removing scales in a mammal susceptible to or suffering from abnormal keratinization, comprising application of a composition of the subject invention. The subject invention is further directed to a method of treating acne in a mammal susceptible to or suffering from acne.

25 The compositions of the subject invention comprise a safe and effective amount of salicylic acid in combination with a safe and effective amount of certain zwitterionic surfactants, and a pharmaceutically-acceptable carrier.

These and other features, aspects and advantages of the subject invention will become better understood with reference to the following description and appended
 30 claims.

DETAILED DESCRIPTION OF THE INVENTION

It has been unexpectedly found that a combination of salicylic acid and certain zwitterionic surfactants exhibits the ability to remove scales from the stratum corneum in mammalian skin and scalp, without undesirable side effects. While the


subject invention is not limited to any particular mode of action, it is believed that the subject combination works by affecting the skin surface's proteolytic enzyme which degrades the protein connections (desmosomes) between cells, thus causing cell or scale shedding. The subject invention thus activates the skin's natural desquamation process at the surface of problem skin.

As used herein "desquamation" means the shedding or removal of scales from the outermost layer (stratum corneum) of the epidermis.

As used herein "treating acne" means preventing, retarding and/or arresting the process of acne formation in mammalian skin.

As used herein, the term "alkyl", unless otherwise indicated, means carbon-containing chains which may be straight or branched, substituted or unsubstituted, saturated or unsaturated. Preferred alkyl are saturated. Preferred alkyl are straight chain. Preferred alkyl are unsubstituted.

As used herein "zwitterionic surfactant" means a compound having the structure:



In structure (I) R^1 is unsubstituted, saturated or unsaturated, straight or branched chain alkyl having from about 9 to about 22 carbon atoms. Preferred R^1 has from about 11 to about 18 carbon atoms; more preferably from about 12 to about 16 carbon atoms; more preferably still from about 14 to about 16 carbon atoms.

In structure (I), m is an integer from 1 to 3, preferably 2 or 3; more preferably 3.

In structure (I), n is either 0 or 1; n is preferably 1.


In structure (I), R^2 and R^3 are, independently, selected from the group consisting of alkyl having from 1 to about 3 carbon atoms, unsubstituted or mono-substituted with hydroxy. Preferred R^2 and R^3 are CH_3 .

In structure (I), X is selected from the group consisting of CO_2 , SO_3 and SO_4 .

In structure (I), R^4 is selected from the group consisting of saturated or unsaturated, straight or branched chain alkyl, unsubstituted or mono-substituted with hydroxy, having from 1 to about 5 carbon atoms. When $\text{X} = \text{CO}_2$, R^4 preferably has 1 or 3 carbon atoms, more preferably 1 carbon atom. When $\text{X} = \text{SO}_3$ or SO_4 , R^4 preferably has from about 2 to about 4 carbon atoms, more preferably 3 carbon atoms.


Preferred zwitterionic surfactants of the subject invention include the following compounds:

a) cetyl betaine:




5

b) cocoamidopropylbetaine:




c) cetyl propyl hydroxy sultaine:




10

d) cocoamidopropyl hydroxy sultaine:



wherein R has from about 9 to about 13 carbon atoms; and

e) behenyl betaine:



15

More preferred zwitterionic surfactants of the subject invention include cetyl betaine, cocoamidopropyl betaine and cetyl propyl hydroxy sultaine. Still more preferred zwitterionic surfactants of the subject invention include cetyl betaine and cocoamidopropyl betaine. The most preferred zwitterionic surfactant of the subject invention is cetyl betaine.

20

As used herein "topical application" means directly laying on or spreading on outer skin.

As used herein, "safe and effective amount" means a sufficient amount of a composition to significantly induce a positive modification in the condition being treated, but low enough to avoid serious side effects.

As used herein "comprising" means that other steps and ingredients which do not affect the end result can be added. This term encompasses the terms "consisting of" and "consisting essentially of".

As used herein, "pharmaceutically-acceptable" means that drugs, medicaments or inert ingredients which the term describes are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, incompatibility, instability, irritation, allergic response and the like.

As used herein, "actives" or "active agents" means a combination of salicylic acid, and a zwitterionic surfactant according to structure (I) or a mixture of such surfactants.

Compositions useful for desquamation preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably about 0.5% to about 2% of salicylic acid or a pharmaceutically-acceptable salt thereof. Preferred pharmaceutically-acceptable salts include alkali metal salts, such as sodium and potassium; alkaline earth metal salts, such as calcium and magnesium; non-toxic heavy metal salts; ammonium salts; and trialkylammonium salts, such as trimethylammonium and triethylammonium.

Compositions useful for desquamation also preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2% of zwitterionic surfactant according to structure (I) or a pharmaceutically-acceptable salt thereof. Preferred pharmaceutically-acceptable salts include alkali metal salts, such as sodium and potassium; alkaline earth metal salts, such as calcium and magnesium; non-toxic heavy metal salts; ammonium salts; and trialkylammonium salts, such as trimethylammonium and triethylammonium.

Pharmaceutically-Acceptable Carrier

In addition to the active agents as described hereinbefore, the pharmaceutical compositions of the present invention essentially comprise a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier", as used herein, means one or more compatible solid or liquid filler diluents which are suitable for administration to a human or lower animal. The term "compatible", as used herein, means that the components of the pharmaceutical compositions are capable of being comingled with the compound of the present invention, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the pharmaceutical composition under ordinary use situations. Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the human or lower animal being treated.

The compositions of the subject invention are administered topically to a biological subject, i.e., by the direct laying on or spreading of the composition on the skin of the subject. The topical compositions useful in the subject invention involve compositions suitable for topical application to mammalian skin, the composition
5 comprising a safe and effective amount of the active agents or mixture of such actives as described hereinafter, and a pharmaceutically-acceptable topical carrier.

The topical compositions useful in the subject invention may be made into a wide variety of product types. These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics. These product types
10 may comprise several types of carrier systems including, but not limited to solutions, emulsions, gels, solids, and liposomes.

The topical compositions useful in the subject invention formulated as solutions typically include a pharmaceutically-acceptable aqueous or organic solvent. The terms "pharmaceutically-acceptable organic solvent" refer to a solvent which is
15 capable of having the actives dispersed or dissolved therein, and of possessing acceptable safety properties (e.g., irritation and sensitization characteristics). Water is a preferred solvent. Examples of suitable organic solvents include: propylene glycol, polyethylene glycol (200-600), polypropylene glycol (425-2025), glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol
20 esters, butanediol, and mixtures thereof. These solutions useful in the subject invention preferably contain from about 80% to about 99.99% of an acceptable aqueous or organic solvent.

If the topical compositions useful in the subject invention are formulated as an aerosol and applied to the skin as a spray-on, a propellant is added to a solution
25 composition. Examples include chloro-fluorinated lower molecular weight hydrocarbons. A more complete disclosure of propellants useful herein can be found in Sagarin, Cosmetics Science and Technology, 2nd Edition, Vol. 2, pp. 443-465 (1972)

Topical compositions useful in the subject invention may be formulated as a
30 solution comprising an emollient. Such compositions preferably contain from about 2% to about 50% of a topical pharmaceutically-acceptable emollient.

As used herein, "emollients" refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin. A wide variety of suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and
35 Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of suitable materials.

A lotion can be made from a solution carrier system. Lotions typically

comprise from about 1% to about 20%, preferably from about 5% to about 10%, of an emollient; and from about 50% to about 90%, preferably from about 60% to about 80%, water.

Another type of product that may be formulated from a solution carrier system is a cream. A cream typically comprises from about 5% to about 50%, preferably from about 10% to about 20%, of an emollient, and from about 45% to about 85%, preferably from about 50% to about 75%, water.

Yet another type of product that may be formulated from a solution carrier system is an ointment. An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous). Ointments may also comprise absorption ointment bases which absorb water to form emulsions. Ointment carriers may also be water soluble. An ointment may comprise from about 2% to about 10% of an emollient; and from about 0.1% to about 2% of a thickening agent. A more complete disclosure of thickening agents useful herein can be found in Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972).

If the carrier is formulated as an emulsion, preferably from about 1% to about 10%, more preferably from about 2% to about 5%, of the carrier system comprises an emulsifier. Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are disclosed in, for example, U.S. Patent 3,755,560, issued August 28, 1973, Dickert et al.; U.S. Patent 4,421,769, issued December 20, 1983, Dixon et al.; and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986).

Preferred emulsions of the subject compositions have low levels of high molecular weight silicones (viscosities of about 50 centistokes or more). More preferred emulsions have viscosities of about 10 centistokes or less. Even more preferred emulsions have viscosities of about 5 centistokes or less. Also preferred emulsions are substantially free of high molecular weight silicones. Anti-foaming compositions are also preferably added because the absence of silicones, in some compositions, may cause foaming upon application. Preferred emulsions of the subject formula are substantially free of occlusives, such as petrolatum, which appear to diminish the zwitterionic effect. Preferred emulsions of the subject compositions are formulated at low pH values, preferably from about 2 to about 4, more preferably about 3. Preferred emulsions of the subject compositions contain humectants, such as glycerin.

The cleaning compositions useful in the subject invention preferably contain from about 1% to about 90%, more preferably from about 5% to about 10%, of a cosmetically-acceptable surfactant.

The physical form of the cleansing compositions is not critical. The compositions can be, for example, formulated as toilet bars, liquids, shampoos, pastes, or mousses. Toilet bars are most preferred since this is the form of cleansing agent most commonly used to wash the skin. Rinse-off cleansing compositions, such as shampoos, require a delivery system adequate to deposit sufficient levels of actives on the skin and scalp. A preferred delivery system involves the use of insoluble complexes. For a more complete disclosure, see U.S. Patent 4, 835,148, Barford et al., issued May 30, 1989; incorporated herein by reference in its entirety.

The surfactant component of the compositions useful in the subject invention are selected from anionic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the detergency art.

The cleaning compositions useful in the subject invention can optionally contain, at their art-established levels, materials which are conventionally used in cleansing compositions. Nonlimiting examples of possible surfactants include isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, and sodium lauryl sulfate. See U.S. Patent No. 4,800,197, to Kowcz et al., issued January 24, 1989, which is incorporated herein by reference in its entirety. Examples of a broad variety of additional surfactants useful herein are described in McCutcheon's, Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation, which is incorporated herein by reference in its entirety.

Combination Actives

A. Anti-Inflammatory Agents

An anti-inflammatory agent may be included as an active along with the active agents, for better activity. A safe and effective amount of an anti-inflammatory agent may be added to the compositions useful in the subject invention, preferably from about 0.1% to about 10%, more preferably from about 0.5% to about 5%, of the composition. The exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency.

Steroidal anti-inflammatory agents, including but not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, flucorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone

acetone, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetone, cortisone, cortodoxone, flucetone, fludrocortisone, difluorosone diacetate, fluradrenolone, 5 fludrocortisone, difluorone diacetate, fluradrenolone acetone, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters, chloroprednisone, chloroprednisone acetate, clocortolone, clescinolone, dichlorisone, diflurprednate, flucoronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, 10 meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, and mixtures thereof may be used. The preferred steroidal anti-inflammatory for use is hydrocortisone.

A second class of anti-inflammatory agents which is useful in the compositions includes the nonsteroidal anti-inflammatory agents. The variety of compounds 15 encompassed by this group are well-known to those skilled in the art. For detailed disclosure of the chemical structure, synthesis, side effects, etc. of non-steroidal anti-inflammatory agents, reference may be had to standard texts, including Anti-inflammatory and Anti-Rheumatic Drugs, K.D. Rainsford, Vol. I-III, CRC Press, Boca Raton, (1985), and Anti-inflammatory Agents, Chemistry and 20 Pharmacology, 1, R.A. Scherrer, et al., Academic Press, New York (1974).

Specific non-steroidal anti-inflammatory agents useful in the composition invention include, but are not limited to:

- 1) the oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP-14,304;
- 25 2) the salicylates, such as aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal;
- 3) the acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, 30 felbinac, and ketorolac;
- 4) the fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids;
- 5) the propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, 35 indoprofen, piroprofen, carprofen, oxaprozin, pranoprofen, mioprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and
- 6) the pyrazoles, such as phenylbutazone, oxyphenbutazone, feprazone,

azapropazone, and trimethazone.

Mixtures of these non-steroidal anti-inflammatory agents may also be employed, as well as the pharmaceutically-acceptable salts and esters of these agents. For example, etofenamate, a flufenamic acid derivative, is particularly useful for
5 topical application. Of the nonsteroidal anti-inflammatory agents, ibuprofen, naproxen, flufenamic acid, mefenamic acid, meclofenamic acid, piroxicam and felbinac are preferred; ibuprofen, naproxen, and flufenamic acid are most preferred.

Finally, so-called "natural" anti-inflammatory agents are useful in methods of the subject invention. For example, candelilla wax, alpha bisabolol, aloe vera,
10 Manjistha (extracted from plants in the genus Rubia, particularly Rubia Cordifolia), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), may be used.

B. Retinoids

In a preferred desquamatory composition useful in the subject invention, a
15 retinoid, preferably retinoic acid, is included as an active along with the active agents. The inclusion of a retinoid increases the desquamation benefits of the composition. A safe and effective amount of a retinoid may be added to the compositions useful in the subject invention, preferably from about 0.001% to about 0.5%, more preferably from about 0.01% to about 0.1% of the composition. As used herein, "retinoid"
20 includes all natural and/or synthetic analogs of Vitamin A or retinol-like compounds which possess the biological activity of Vitamin A in the skin as well as the geometric isomers and stereoisomers of these compounds, such as all-trans retinoic acid and 13-cis-retinoic acid.

C. Antimicrobial Agents

25 In a preferred composition useful in the subject invention, an antimicrobial agent is included as an active along with the active agents. The inclusion of an antimicrobial agent increases the desquamation benefits of the composition. As used herein, "antimicrobial agent" means a compound capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of
30 microbes.

A safe and effective amount of an antimicrobial agent may be added to compositions useful in the subject invention, preferably from about 0.001% to about 5%, more preferably from about 0.01% to about 2%, more preferably still from about 0.05% to about 1% of the compositions. Preferred antimicrobial agents useful in the
35 subject invention are benzoyl peroxide, erythromycin, tetracycline, clindamycin, azelaic acid, and sulfur resorcinol.

D. Antiandrogens

In a preferred composition useful in the subject invention, an antiandrogen is included as an active along with the active agents. As used herein, "antiandrogen" means a compound capable of correcting androgen-related disorders by interfering with the action of androgens at their target organs. The target organ for the subject invention is mammalian skin.

E. Sunscreens and Sunblocks

Exposure to ultraviolet light can result in excessive scaling of the stratum corneum. Therefore, in a preferred composition useful in the subject invention, a sunscreen or sunblock is included as an active along with the actives of the subject invention.

A wide variety of conventional sunscreens are suitable for use in combination with the desquamation agents. Sagarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology, disclose numerous suitable agents, incorporated herein by reference. Specific suitable sunscreens include, for example: p-aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid); anthranilates (i.e., o-aminobenzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and dipropylene glycol esters); Cinnamic acid derivatives (menthyl and benzyl esters, a-phenyl cinnamitrile; butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylaceto-umbelliferone); trihydroxycinnamic acid derivatives (esculetin, methylesculetin, daphnetin, and the glucosides, esculin and daphnin); hydrocarbons (diphenylbutadiene, stilbene); dibenzalacetone and benzalacetophenone; naphtholsulfonates (sodium salts of 2-naphthol-3,6-disulfonic and of 2-naphthol-6,8-disulfonic acids); dihydroxy-naphthoic acid and its salts; o- and p-Hydroxybiphenyldisulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl naphthoxazole, various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate, and tannate); quinoline derivatives (8-hydroxyquinoline salts, 2-phenylquinoline); hydroxy- or methoxy-substituted benzophenones; uric and vilouric acids; tannic acid and its derivatives (e.g., hexaethylether); (butyl carbotol) (6-propyl piperonyl) ether; hydroquinone; benzophenones (oxybenzene, sulisobenzene, dioxybenzene, benzo-resorcinol, 2,2',4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzene; 4-isopropylidibenzoylmethane; butylmethoxydibenzoylmethane;

etocrylene; [3-(4'-methylbenzylidene bornan-2-one) and 4-isopropyl-di-benzoylmethane.

Of these, 2-ethylhexyl-p-methoxycinnamate, 4,4'-t-butyl methoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, octyl-
 5 dimethyl-p-aminobenzoic acid, digalloyltriolate, 2,2-dihydroxy-
 -4-methoxybenzophenone, ethyl-4-(bis(hydroxypropyl))aminobenzoate,
 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexylsalicylate,
 glyceryl-p-aminobenzoate, 3,3,5-trimethylcyclohexylsalicylate, methylanthranilate, p-
 -dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-
 10 -dimethylamino-benzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethyl-
 aminophenyl)-5-sulfonicbenzoxazoic acid and mixtures of these compounds, are preferred.

More preferred sunscreens useful in the compositions useful in the subject invention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoylmethane,
 15 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid and mixtures thereof.

Also particularly useful in the compositions are sunscreens such as those disclosed in U.S. Patent No. 4,937,370 issued to Sabatelli on June 26, 1990, and U.S. Patent No. 4,999,186 issued to Sabatelli & Spirnak on March 12, 1991, both of
 20 which are incorporated herein by reference. The suncreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra-violet radiation absorption spectra. One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.

Preferred members of this class of sunscreening agents are
 25 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of 2,4-dihydroxybenzophenone; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl) methylaminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl)methylaminobenzoic acid ester of
 30 2-hydroxy-4-(2-hydroxyethoxy)benzophenone; 4-N,N-(2-ethylhexyl)-methylamino-benzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone; and N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane and mixtures thereof.

35 A safe and effective amount of sunscreen may be used as an added active in compositions useful in the subject invention. The sunscreening agent must be compatible with the desquamation agents. The composition preferably comprises

from about 1% to about 20%, more preferably from about 2% to about 10%, of a sunscreensing agent. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF).

An agent may also be added to any of the compositions useful in the subject invention to improve the skin substantivity of those compositions, particularly to enhance their resistance to being washed off by water, or rubbed off. A preferred agent which will provide this benefit is a copolymer of ethylene and acrylic acid. Compositions comprising this copolymer are disclosed in U.S. Patent 4,663,157, Brock, issued May 5, 1987, which is incorporated herein by reference.

10 F. Anti-Oxidants/Radical Scavengers

In a preferred composition of the subject invention, an anti-oxidant/radical scavenger is included as an active along with the active desquamation agents. Anti-oxidants/radical scavengers enhance the desquamation benefits of the subject invention by providing additional protection against UV radiation which can cause increased scaling in the stratum corneum.

A safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions useful in the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition.

20 Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, tocopherol (vitamin E), tocopherol sorbate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox^R), gallic acid and its alkyl esters, especially propyl
25 gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, the ascorbyl esters of fatty acids, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), and dihydroxy fumaric acid and its salts may be used.

G. Chelators

30 In a preferred desquamatory composition useful in the subject invention, a chelating agent is included as an active along with the active agents. As used herein, "chelating agent" means an active agent capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze chemical reactions. The inclusion of a chelating agent increases the
35 desquamation benefits of the composition by providing added protection against UV radiation which can contribute to excessive scaling.

A safe and effective amount of a chelating agent may be added to the

compositions useful in the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition. Chelators useful in compositions are disclosed in U.S. Patent Application Serial No. 619,805, Bissett, Bush & Chatterjee, filed November 27, 1990 (which is a continuation of U.S. Patent Application Serial No. 251,910, filed October 4, 1988); U.S. Patent Application Serial No. 514,892, Bush & Bissett, filed April 26, 1990; and U.S. Patent Application Serial No. 657,847, Bush, Bissett & Chatterjee, filed February 25, 1991; all incorporated herein by reference. Preferred chelators useful in compositions of the subject invention are furildioxime and derivatives thereof.

10 H. Anti-dandruff Actives

In a preferred composition of the subject invention formulated for application to the scalp, an anti-dandruff agent is included as an active along with the active desquamation agents. Anti-dandruff agents enhance the desquamation benefits of the subject invention by further preventing and treating the effects of flaking on the scalp.

15 A particularly preferred anti-dandruff agent is zinc pyridinethione.

I. Glycolic Acid

In a preferred composition of the subject invention, glycolic acid is included as an active along with the subject desquamation agents. Preferably, the composition comprises from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2% glycolic acid.

20

Delivery Methods for the Topical Compositions

The topical compositions useful for the methods of the instant invention can be delivered from a variety of delivery devices. The following are two nonlimiting examples.

25 Medicated Cleansing Pads

The compositions useful herein can be incorporated into a medicated cleansing pad. Preferably these pads comprise from about 50% to about 75% by weight of one or more layers of nonwoven fabric material and from about 20% to about 50% by weight of a liquid composition deliverable from the nonwoven fabric material comprising hydroxy acid comprising salicylic acid and a subject zwitterionic surfactant, or mixture of such surfactants. These pads are described in detail in U. S. Patent No. 4,891,228, to Thaman et al., issued January 2, 1990; and U. S. Patent No. 4,891,227, to Thaman et al., issued January 2, 1990; both of which are incorporated by reference herein in their entirety.

35 Dispensing Devices

The compositions useful herein can also be incorporated into and delivered from a soft-tipped or flexible dispensing device. These devices are useful for the

controlled delivery of the compositions to the skin surface and have the advantage that the treatment composition itself never need be directly handled by the user. Nonlimiting examples of these devices comprise a fluid container including a mouth, an applicator, means for holding the applicator in the mouth of the container, and a
5 normally closed pressure-responsive valve for permitting the flow of fluid from the container to the applicator upon the application of pressure to the valve. The fluid comprises hydroxy acid comprising salicylic acid and a subject zwitterionic surfactant, or mixture of such surfactants.

The valve can include a diaphragm formed from an elastically fluid
10 impermeable material with a plurality of non-intersecting arcuate slits therein, where each slit has a base which is intersected by at least one other slit, and where each slit is out of intersecting relation with its own base, and wherein there is a means for disposing the valve in the container inside of the applicator. Examples of these applicator devices are described in U.S. Patent No. 4,693,623, to Schwartzman,
15 issued September 15, 1987; U.S. Patent No. 4,620,648, to Schwartzman, issued September 15, 1987; U.S. Patent No. 3,669,323, to Harker et al., issued June 13, 1972; U.S. Patent No. 3,418,055, to Schwartzman, issued December 24, 1968; and U.S. Patent No. 3,410,645, to Schwartzman, issued November 12, 1968; all of which are incorporated herein by reference in their entirety. Examples of applicators useful
20 herein are commercially available from Dab-O-Matic, Mount Vernon, NY.

METHODS FOR DESQUAMATION AND TREATMENT OF ACNE

The subject invention relates to methods of removing scales from the stratum corneum of mammals. Such methods comprise topically applying to the skin or scalp an effective amount of the compositions of the subject invention. The term "effective
25 amount", as used herein, means an amount sufficient to provide a scale removal benefit. The composition can be applied for several days, weeks, months or years at appropriate intervals: from about three times a day to about once every three days, preferably from about twice a day to once every other day, also preferably about once a day until satisfactory desquamation has been achieved.

30 The subject compositions may also be used for one or more of the following: reducing the appearance of large pores, reducing imperfections and/or blemishes in skin color, relieving dryness, eliminating dry rough spots, improving the skin's ability to retain moisture and/or protect itself from environmental stresses, reducing the appearance of fine lines and wrinkles, improving appearance and skin tone, increasing
35 skin firmness and/or suppleness, increasing skin glow and clarity, and/or increasing the skin renewal process.

Typically, in each application, an effective coating of the skin or scalp is

achieved by applying from about $0.004\text{mg}/\text{cm}^2$ to about $0.1\text{ mg}/\text{cm}^2$ each of hydroxy acid comprising salicylic acid and a subject zwitterionic surfactant, or mixture of such surfactants, more preferably from about $0.02\text{mg}/\text{cm}^2$ to about $0.06\text{mg}/\text{cm}^2$, also preferably about $0.04\text{ mg}/\text{cm}^2$.

5

Examples

The following examples further describe and demonstrate embodiments within the scope of the subject invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the subject invention, as many variations thereof are possible without departing from the spirit
10 and scope of the invention.

Example I

A topical composition is prepared by combining the following components utilizing conventional mixing techniques.

	<u>Ingredient</u>	<u>% Weight</u>
5	Water	50.67
	Triethanolamine	0.66
	Cetyl Betaine	6.66
	Disodium EDTA	0.01
	Ethanol (95%)	40.00
10	Salicylic Acid	2.00

The above composition is applied to the face to remove scales at a dose enough to deposit 2 mg of the composition per cm² skin, once a day. As desquamation progresses, application is reduced to once very other day.

Example II

15 A cleaning composition is prepared by combining the following ingredients, using conventional mixing techniques:

	<u>Ingredient</u>	<u>% Weight</u>
	Water	44.75
	Tetrasodium EDTA	0.12
20	Cetyl Betaine	3.33
	Sodium methyl cocoyl taurate	41.67
	Cocoamidopropyl hydroxysultaine	6.00
	Salicylic Acid	2.00
	Cocoamidopropyl betaine	1.43
25	Hydroxypropyl methylcellulose	0.50
	Glycolic Acid	0.20
	Perfume	0.12

30 The cleaning composition is applied to the face twice a day to treat acne. An amount enough to deposit 3 mg of the composition per cm² skin is used. As existant acne subsides, frequency is reduced to once a day.

Example III

The following hair tonic is prepared by mixing the ingredients according to conventional mixing techniques:

	<u>Ingredient</u>	<u>% Weight</u>
35	Triethanolamine lauryl sulfate	17.0
	Coconut diethanol amide	2.0
	Hydroxypropyl methyl cellulose ¹	0.2

	Corn syrup (80% solids) ²	30.0
	Dimethylpolysiloxane	1.0
	Cationic cellulose ³	0.5
	Ethyl alcohol (SDA 40)	9.0
5	Vinyl carboxy polymer ⁴	0.7
	Salicylic acid	1.5
	Cocoamidopropyl Betaine	3.5
	Perfume, color, preservative	1.0
	Water	33.6
10	Acid or base to pH 6.5	
	¹ Methocel E4M (Dow Chemical)	
	² 42 Dextrose equivalent (Staley 1300)	
	³ Polymer JR 400	
	⁴ Carbopol 941 (BF Goodrich)	
15	The composition is applied to the scalp every other day to treat dandruff. A dose of 5 mg of the composition per cm ² skin is applied and then washed off.	

Example IV

The following topical gel is prepared by mixing the ingredients according to conventional mixing techniques:

20	<u>Ingredients</u>	<u>% Weight</u>
	Alcohol SD-40 (95%)	40.00
	Salicylic Acid	2.00
	Disodium EDTA	0.005
	Cetyl Betaine	6.66
25	Water	47.335

The gel is applied to the face at a dose of 0.2 mg composition per cm² skin three times a day to remove scales. As desquamation progresses, application may be reduced to once a day.

Example V

The following lotion is prepared by mixing the ingredients according to conventional mixing techniques:

	<u>Ingredient</u>	<u>% Weight</u>
	Water	q.s
35	Glycerin	10.0
	Petrolatum	2.5
	Cetyl Alcohol	1.8

	Cyclomethicone and Dimethicone Copolyol	1.5
	Stearyl Alcohol	1.2
	Isopropyl Palmitate	1.0
	Dimethicone	0.5
5	Sodium Hydroxide	0.34
	Lanolin Acid	0.25
	Polyethyleneglycol-100 Stearate	0.25
	Stearic Acid	0.25
	Methylparaben	0.2
10	Titanium Dioxide	0.15
	EDTA	0.1
	Salicylic Acid	4.0
	Cocoamidopropyl Betaine	5.0

The above lotion is applied to the hands once a day at a dose of .75 mg composition per cm² skin. As desquamation progresses, frequency of application may be reduced to once every two days.

Example VI

The following emulsion is prepared by mixing the following ingredients according to conventional mixing techniques:

20	<u>Ingredient</u>	<u>% Weight</u>
	Water	q.s.
	PPG-14 Butyl Ether	8.0
	Cetyl Betaine	2.0
	Glycerin	4.0
25	Salicylic Acid	2.0
	Stearyl Alcohol	1.5
	Salcare SC 95	1.5
	Cetyl Alcohol	1.5
	Dimethicone	1.0
30	Silica (DC Antifoam)	0.5
	Steareth-21	0.45
	Steareth-2	0.05
	Tetrasodium EDTA	0.02

The above lotion is applied to the face once a day at a dose of .60 mg composition per cm² skin. As desquamation progresses, frequency of application may be reduced to once every two days.


While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of the subject invention.

What is Claimed is:

1. A pharmaceutical composition comprising:

a) desquamation actives consisting essentially of:

(i) a safe and effective amount, preferably from 0.1% to 10% of a zwitterionic surfactant having the structure:



wherein R¹ is unsubstituted, saturated or unsaturated, straight or branched chain alkyl having from 9 to 22 carbon atoms; m is an integer from 1 to 3; n is 0 or 1; R² and R³ are, independently, alkyl having from 1 to 3 carbon atoms, unsubstituted or mono-substituted with hydroxy; R⁴ is saturated or unsaturated, straight or branched chain alkyl, unsubstituted or mono-substituted with hydroxy, having from 1 to 5 carbon atoms; and X is selected from the group consisting of CO₂, SO₃ and SO₄; and

(ii) a safe and effective amount, preferably from 0.1% to 10% of salicylic acid; and

b) a topical carrier.

2. The composition of Claim 1 wherein:

a) R² and R³ are selected from the group consisting of CH₃, CH₂CH₂OH and CH₂CH₂CH₂OH;

b) X is CO₂ or SO₃;

c) m is 2 or 3; and

d) R⁴ has from 1 to 3 carbon atoms when X is CO₂; and R⁴ has from 2 to 4 carbon atoms when X is SO₃.

3. The composition of any of Claims 1 or 2 wherein:
 - a) R^1 has from 11 to 18 carbon atoms;
 - b) R^2 and R^3 are CH_3 ; and
 - c) R^4 has 1 carbon atom when X is CO_2 ; and R^4 has 3 carbon atoms when X is SO_3 .
4. The composition of any of Claims 1, 2 or 3 wherein:
 - a) R^4 has 1 carbon atom;
 - b) X is CO_2 ;
 - c) m is 3; and
 - d) n is 1.
5. The composition of any of Claims 1, 2 or 3 wherein:
 - a) R^4 has 3 carbon atoms;
 - b) X is SO_3 ;
 - c) m is 3; and
 - d) n is 1.
6. The composition of any of Claims 1, 2, 3, 4 or 5 wherein:
 - a) the concentration of salicylic acid is from 0.2% to 5%;
 - b) the concentration of zwitterionic surfactant is from 0.2% to 5%; and
 - c) the composition further comprises from 0.2% to 5% of glycolic acid.

7. The composition of any of Claims 1, 2 or 3 wherein the zwitterionic surfactant is selected from the group consisting of behenyl betaine, cocoamidopropyl betaine, cetyl propyl hydroxy sultaine and cetyl betaine, preferably cetyl betaine.
8. Use of a composition according to any of Claims 1, 2, 3, 4, 5, 6 or 7, for manufacture of a medicament for achieving desquamation of mammalian skin wherein the medicament is to be applied topically to the skin of a mammal in need of treatment.
9. Use of a composition according to any of Claims 1, 2, 3, 4, 5, 6 or 7, for manufacture of a medicament for treating acne in mammalian skin wherein the medicament is to be applied topically to the skin of a mammal in need of treatment.
10. Use of a composition according to any Claims 8 or 9 wherein:
 - a) the amount of salicylic acid applied is from 0.004 mg/cm² skin to 0.1 mg/cm² skin; preferably from 0.02 mg/cm² skin to 0.06 mg/cm² skin; and
 - b) the amount of zwitterionic surfactant applied is from 0.004 mg/cm² skin to 0.1 mg/cm² skin; preferably from 0.02 mg/cm² skin to 0.06 mg/cm² skin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/12745

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K7/48 A61K31/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 7850, Derwent Publications Ltd., London, GB; AN 78-003127 & RO,A,64 162 (MIRAJ INTR COSMETIC) 31 March 1978 see abstract	1,8
P,X	WO,A,94 09755 (BEIERSDORF AG) 11 May 1994 see example 4	1-4,7,8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

30 January 1995

Date of mailing of the international search report

17.02.95

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/12745

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9409755	11-05-94	NONE	